Merck: adjusted NP-27% at nearly $4bn
(CercleFinance.com) - Merck announces that sales reached $16.
65bn in Q3, up 4% (or +7% at constant exchange rates). NB cp -4%.
Adjusted net income came to $3.98bn, down 27% (or -23% at constant exchange rates), leaving adjusted EPS of $1.57, down 26% (-23% at constant exchange rates), ahead of expectations, but including a net charge of $0.79 per share related to certain business development transactions.
Our third-quarter results were solid, as we continue to make progress toward 2025 and beyond, it said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
65bn in Q3, up 4% (or +7% at constant exchange rates). NB cp -4%.
Adjusted net income came to $3.98bn, down 27% (or -23% at constant exchange rates), leaving adjusted EPS of $1.57, down 26% (-23% at constant exchange rates), ahead of expectations, but including a net charge of $0.79 per share related to certain business development transactions.
Our third-quarter results were solid, as we continue to make progress toward 2025 and beyond, it said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.